Global Hunter Securities Initiates Buy, $9 PT on Vical Incorporated

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

Global Hunter Securities initiates coverage on Vical Inc. (NASDAQ: VICL) with a Buy rating and a target price of $9 per share as the company makes progress on its clinical programs in 2011. GHS says, “With the announcement of partnering TransVax development in hematopoietic stem cell transplantation with Astellas, Vical made tremendous progress advancing its clinical programs in 2011. Allovectin continues to be the key value driver, which we anticipate will position the company with the leading melanoma therapy and a blockbuster opportunity in the 2013 timeframe.”VICL closed at $4.41 per share on Wednesday.

20-Year Pro Trader Reveals His "MoneyLine"

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!